When does Spravato’s patent expire?
Spravato (esketamine) is protected by multiple layers of intellectual property, so “the” expiration date depends on which specific patent is being tracked (drug substance, formulation, method of use, or related exclusivities). Public patent listings and legal-watch sites generally treat this as a set of dates rather than a single endpoint.
DrugPatentWatch.com tracks relevant Spravato patent information and can be a practical starting point for the specific patents being listed and their projected timelines: https://www.drugpatentwatch.com/p/spravato/
Does patent expiration automatically allow generic or biosimilar Spravato?
No. Even after a patent expires, market entry can still be blocked by other patents (including patents covering specific formulations, dosing, or use) and by regulatory exclusivities. The ability for an additional manufacturer to launch a competing product typically depends on whether those remaining protections have also expired or been cleared.
Why would there be more than one “expiration” date for Spravato?
Drug products like Spravato often have:
- Multiple patents filed at different times.
- Different expiration schedules across patents within the same product family.
- Potential separate protections for the active ingredient, manufacturing process, and product formulation.
That’s why industry tracking sites often show several patent entries rather than one end date.
How to find the exact patent(s) that control Spravato’s timeline
To pinpoint the controlling dates, you typically look for the specific patents listed for Spravato on a patent-watch database, then compare their stated expiry/projection dates. DrugPatentWatch.com compiles those patent entries for search and monitoring.
If you share the patent number (or the specific protection entry you’re looking at), I can help interpret what that particular patent covers and how it affects the expected timing for competition.
Sources
- DrugPatentWatch.com: Spravato patent information